Exploristics Board
Professor Chris Molloy
Chris Molloy has an extensive 30-year international board and executive career in the life sciences sector. Starting in preclinical science and research management at GlaxoSmithKline, Chris has held a variety of roles including COO of MerLion Pharmaceuticals a multinational anti-infectives biotechnology company and has run corporate development for the global informatics firm, idbs. Chris was also CEO for three years at the RSA Group, the global life science executive search specialist.
Read More
He is currently CEO of the Medicines Discovery Catapult, the national research technology facility supporting the sector by industrialising and driving the adoption of new R&D techniques for discovering medicines and is Director of the UK Lighthouse Labs Network, the national diagnostic lab network created to support the fight against COVID-19. He is also non-executive chairman of NorthWest EHealth, a private UK tech company using real-world healthcare data to improve clinical development. He chairs the IP Advisory Committee for the Association of Medical Research Charities and the Industry Advisory Board for the Biomedical Research Centre & Health Innovation Manchester. Chris is a member of the Institute of Cancer Research and holds an honorary chair at the University of Manchester.
Dr. Aiden Flynn
After seven years as a Lecturer at University College London, Aiden spent ten years at GlaxoSmithKline as a Director of Statistical Support for Biomarker Studies across research and development before founding Exploristics in 2009.
Read More
At Exploristics, Aiden has created an innovative and profitable company and overseen its ongoing growth and transition from a specialist statistics consultancy to a provider of innovative statistical software such as the KerusCloud platform with wrap-around biostatistics support. As such, Exploristics caters to a wide range of global healthcare developers from the world’s top pharmaceutical companies to biotechnology, medical device and diagnostic start-ups.
With key expertise in emerging approaches to clinical development such as Precision Medicine and biomarker discovery, validation and integration, Aiden has worked closely with regulatory authorities, such as the FDA and EMA, to develop tools and guidelines that support the use of biomarkers in clinical studies. He has over 40 publications in peer reviewed journals and books and is an invited speaker at international conferences. Aiden is also a member of the Precision Medicine Advisory Board at Merck Biopharm and is involved in the Precision Medicine Steering Group, offering strategic advice to the Department of Health. He is also Commercial Director on the Board of Directors at PSI.
Susan Clement-Davies
Susan Clement-Davies is an experienced life sciences financier with over 25 years of capital markets and investment banking experience, including as Managing Director of Equity Capital Markets at Citigroup Global Markets and Managing Director at Torreya Partners LLC, a global investment bank serving the life sciences industry.
Read More
She is currently Non-Executive Director and Chairman of the Audit Committee of Evgen Pharma plc, an AIM-listed clinical-stage drug development company, and is Corporate Finance Advisor for Theolytics, a biotechnology company developing anticancer viral therapies. She also holds a position as Non-Executive Director on the Board of Scancell Holdings, a developer of novel immuno-oncology therapies, and is on the Innovations Advisory Board at Chelsea & Westminster NHS Trust Hospital.
Donal Carville
Donal Carville has nearly twenty years’ experience in corporate and investment banking. From 2005 Donal worked at Mizuho where he helped establish, build and run a business focused on longevity risk.
Read More
Prior to Mizuho, Donal spent more than a decade at Citigroup, where he became a Managing Director and member of the Senior Management Team within its Capital Structuring group. He is currently Founder and CEO of fintech company Circadian Capital, focusing on data analytics, cybersecurity, and cloud computing.